Sara Ashlyn Penquite, M.D.
Endocrinology, Diabetes & Metabolism Physician · Tucson, AZ
Sara Ashlyn Penquite, M.D. is an endocrinology, diabetes & metabolism physician with a practice address in Tucson, Arizona, and NPI 1528591682, issued on Apr 6, 2017. Check the license (Arizona R77937, as entered in NPPES) on the Arizona Medical Board; the Medicare figures below come from public CMS files.
- Name
- Sara Ashlyn Penquite
- Credential
- M.D.
- Primary taxonomy
- Endocrinology, Diabetes & Metabolism Physician 207RE0101X
- License number
- R77937 AZ
Self-reported in NPPES; status is on the state search - Practice location
- 3838 N Campbell Ave Bldg 2, Tucson, AZ 85719
- Phone
- (520) 694-8888
- Enumerated
- Apr 6, 2017
- Record last updated
- Mar 21, 2022
- Fax
- (520) 874-2251
- Medicare enrollment
- Enrolled (PECOS I20220518001866); accepts Medicare assignment
- Medical or professional school
- University Of Arizona College Of Medicine, 2017
- Telehealth
- Offers telehealth (CMS)
- Entity
- Type 1 · individual
Also registered at 3838 N Campbell Ave Bldg 2
A shared address usually means a shared clinic or building; it does not show who employs whom.
- Joseph Alpert, MDCardiovascular Disease Physician1265404446
- Desiree Anguiz, FNP-BCFamily Nurse Practitioner1205605581
- Hossein Ardehali, MDCardiovascular Disease Physician1184750945
- Esteban Astiazaran Symonds, M.D,Clinical Genetics (M.D.) Physician1346625357
- Frank Brosius, MDNephrology Physician1336221217
- Alexa Carbone-Lang, RD, LDRegistered Dietitian1538839899
Verify Sara Ashlyn Penquite in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersArizona Medical Board
Search for license R77937Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
53% fewer Medicare Part D claims than the average endocrinology, diabetes & metabolism physician in 2024
1,246 Medicare Part D claims for 212 beneficiaries, against an average of 2,630 among the 8,223 providers of this specialty who prescribed in Part D. Brand-name drugs were 52% of claims.
Most prescribed
- Levothyroxine Sodium171 claims
- Trulicity77 claims
- Mounjaro57 claims
- Lantus Solostar48 claims
- Ozempic48 claims
- Hydrocortisone47 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
The MIPS final score for 2023 (Medicare payment program): 97.6 of 100
The Merit-based Incentive Payment System score is reported for this clinician. Four categories are weighted into the final score; the average among 454,083 clinicians with a measured score was 83.5.
Source: CMS Quality Payment Program, MIPS performance year 2023; category weights for 2023 (qpp.cms.gov).
Industry payments in 2024: $2,142.10
14 payments; by number, the most common kind was food and beverage; the largest payer was Medtronic, Inc. The 5,661 providers of this specialty with any payment received $5,742.15 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.
Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.
Bills Medicare through one group practice
- Banner-University Medical GroupTucson, AZ
Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).
Endocrinology, Diabetes & Metabolism Physician providers in Arizona
There are 175 endocrinology, diabetes & metabolism physician records in Arizona.
Other endocrinology, diabetes & metabolism physician records in Arizona
- Rtika Abraham, MDPhoenix, AZ1689803173
- Dima Abu Afifeh, MDTucson, AZ1144924325
- Rashi Agarwal, M.D.Peoria, AZ1336394956
- Seema Ahluwalia, M.D.Chandler, AZ1447231147
- Adnan Ajmal, MDPhoenix, AZ1245494046
- Yasmin Akhunji, M.D.Phoenix, AZ1790918738
- Osamah Al Ali, MDScottsdale, AZ1407485337
- Ahmad Al Maradni, MDPhoenix, AZ1588194112
- Abdul-Razzak Alamir, MDScottsdale, AZ1841263662
- Karissa Aldrete, MDPhoenix, AZ1134682594
Common questions
What is Sara Ashlyn Penquite, M.D.'s NPI number?
Sara Ashlyn Penquite, M.D.'s National Provider Identifier (NPI) is 1528591682, issued on Apr 6, 2017. An NPI identifies a provider in billing; it is not a license.
Where is Sara Ashlyn Penquite, M.D. located?
The NPPES record lists a practice address at 3838 N Campbell Ave Bldg 2, Tucson, AZ, 85719. Phone: (520) 694-8888. Providers update this record themselves, so call before visiting.
How can I verify Sara Ashlyn Penquite, M.D.'s license?
NPPES lists Arizona license number R77937, as entered by the provider. Search the Arizona Medical Board at https://www.azmd.gov/. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.
How much does Sara Ashlyn Penquite, M.D. prescribe under Medicare Part D?
In 2024, Sara Ashlyn Penquite, M.D. had 1,246 Medicare Part D claims for 212 beneficiaries; the average among endocrinology, diabetes & metabolism physician prescribers was 2,630. Part D covers Medicare prescriptions only.
What is Sara Ashlyn Penquite, M.D.'s MIPS final score?
The 2023 MIPS final score is 97.6 of 100. The average among 454,083 clinicians with a measured score was 83.5.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.